1. FDA. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). 14 Jun 2016. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin. Accessed 9 July 2020.
2. The Committee on the Proper Use of SI. Recommendations on the proper use of SGLT2 inhibitors. Diabetology International. 2019 2019/11/15.
3. PMDA. PMDA revises a label tofogliflozin. 9 Jan 2015. (In Japanese). https://www.info.pmda.go.jp/kaiteip/20150109A002/03.pdf. Accessed 9 July 2020.
4. PMDA. PMDA revises labels ipragliflozin, dapagliflozin, luseogliflozin, canagliflozin, and empagliflozin. 9 Jan 2015. (In Japanese). https://www.info.pmda.go.jp/kaiteip/20150109A002/02.pdf. Accessed 9 July 2020.
5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.